Neurelis, Inc.
Neurelis is a neuroscience-based company dedicated to developing life-changing treatments for neurological conditions, especially epilepsy. Founded in 2007 in San Diego, California, the company focuses on innovative therapies that empower people with neurological disorders, care partners, and healthcare providers. Their mission is to develop products, technologies, and programs that improve lives and address unmet medical needs in CNS disorders.
Industries
Nr. of Employees
medium (51-250)
Neurelis, Inc.
3430 Carmel Mountain Road, Suite 300, San Diego, CA 92121
Patents
Products
Intranasal diazepam rescue formulation (approved for acute seizure clusters)
An intranasal diazepam formulation developed using transmucosal absorption enhancement to enable noninvasive, rapid at‑home treatment of seizure clusters; supported by pediatric and adult clinical safety and PK studies.
Investigational intranasal small‑molecule rescue formulation for acute psychiatric agitation
Early clinical‑stage intranasal small‑molecule formulation being developed for rapid control of acute agitation related to psychiatric disorders.
Early‑stage CNS Rho kinase (ROCK) inhibitor program (investigational NCE)
Preclinical/early clinical small‑molecule Rho kinase inhibitor program acquired for treatment development in rare CNS vascular disorders, with IND plans and preclinical support from NIH SBIR funding.
Intranasal diazepam rescue formulation (approved for acute seizure clusters)
An intranasal diazepam formulation developed using transmucosal absorption enhancement to enable noninvasive, rapid at‑home treatment of seizure clusters; supported by pediatric and adult clinical safety and PK studies.
Investigational intranasal small‑molecule rescue formulation for acute psychiatric agitation
Early clinical‑stage intranasal small‑molecule formulation being developed for rapid control of acute agitation related to psychiatric disorders.
Early‑stage CNS Rho kinase (ROCK) inhibitor program (investigational NCE)
Preclinical/early clinical small‑molecule Rho kinase inhibitor program acquired for treatment development in rare CNS vascular disorders, with IND plans and preclinical support from NIH SBIR funding.
Services
Multichannel patient support including nurse educator access, instructional materials, pharmacy connection assistance and patient assistance/savings enrollment support.
Business development services to structure regional licensing and commercialization agreements, pursue in‑licensing or acquisitions, and monetize royalty or receivable streams.
Preparation and delivery of scientific content, poster and oral presentations at medical congresses, and maintenance of HCP-directed medical resources.
Multichannel patient support including nurse educator access, instructional materials, pharmacy connection assistance and patient assistance/savings enrollment support.
Business development services to structure regional licensing and commercialization agreements, pursue in‑licensing or acquisitions, and monetize royalty or receivable streams.
Preparation and delivery of scientific content, poster and oral presentations at medical congresses, and maintenance of HCP-directed medical resources.
Expertise Areas
- Transmucosal and intranasal drug delivery development
- Clinical trial management for CNS indications including pediatric studies
- Clinical pharmacokinetics and population PK modeling
- Regulatory strategy and FDA interactions (IND/NDA and designation pathways)
Key Technologies
- Transmucosal absorption enhancement
- Intranasal spray formulation and delivery systems
- Hydrogel-based stabilization and excipient systems
- Formulation approaches for peptides, proteins and small molecules
News & Updates
Neurelis concluded a pre-IND meeting with the FDA regarding NRL-4, which is being investigated as a noninvasive, easy-to-administer rescue treatment for acute agitation in adults with schizophrenia and bipolar 1 mania.
The FDA approved VALTOCO for short-term treatment of seizure clusters in children aged 2 years and older, highlighting its safety and efficacy in early childhood.
Neurelis announced details of its presentations at AES, including analyses of immediate-use seizure medication for treatment of seizure clusters.
Neurelis concluded a pre-IND meeting with the FDA regarding NRL-4, which is being investigated as a noninvasive, easy-to-administer rescue treatment for acute agitation in adults with schizophrenia and bipolar 1 mania.
The FDA approved VALTOCO for short-term treatment of seizure clusters in children aged 2 years and older, highlighting its safety and efficacy in early childhood.
Neurelis announced details of its presentations at AES, including analyses of immediate-use seizure medication for treatment of seizure clusters.